Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew Xiuxuan Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018

Cited by 2,474 works. doi:10.1016/s1470-2045(18)30351-6

Authors

References